This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
INVEGA HAFYERA® (paliperidone palmitate 6-month)
Medical Information
Use of INVEGA HAFYERA in Patients with Comorbid Substance Abuse
Last Updated: 09/10/2025
Summary
- INVEGA HAFYERA has not been studied in patients with comorbid substance abuse.
- A diagnosis of moderate or severe substance use disorder (except for nicotine and caffeine) within 6 months of screening was an exclusion criterion in the pivotal INVEGA HAFYERA trial.1
- Patients in the study were strongly encouraged not to use alcohol, illicit substances, or recreational marijuana during the study. Medical marijuana was strictly prohibited.2
- A diagnosis of moderate or severe substance use disorder (except for nicotine and caffeine) within 6 months of screening was an exclusion criterion in the pivotal INVEGA HAFYERA trial.1
A literature search of MEDLINE®
References
| 1 | Najarian D, Sanga P, Wang S, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022;25(3):238-251. |
| 2 |
Would you like to clear and leave your conversation? Message history will be lost.